Early clinical experience with a novel rapamycin derivative.
about
Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipientsEverolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the ratTherapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data.Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer.Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors.Cyclosporin therapeutic drug monitoring--an established service revisited.Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.Chronic allograft nephropathy: pathogenesis and management of an important posttransplant complication.Future immunosuppressive agents in solid-organ transplantation.Interactions of everolimus and sorafenib in whole blood lymphocyte proliferation.The promise of mTOR inhibitors in the treatment of colorectal cancer.Everolimus in the treatment of hormone receptor-positive breast cancer.Everolimus and sirolimus in transplantation-related but different.Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.De novo mTOR inhibitor-based immunosuppression in ABO-incompatible kidney transplantation.mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling.Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients.Everolimus is a potent inducer of erythroid differentiation and gamma-globin gene expression in human erythroid cells.
P2860
Q24246340-546D9545-FE0B-4E06-B8A5-E12F68A2ED18Q28484671-A8EADADD-4970-4204-A89B-ADB783BDDC83Q30983921-07D1BF6E-DBCB-4FFF-BE42-50321B024A51Q34009045-A958DB61-1115-4600-9C70-43F056D25B2AQ34546358-CB2873C4-D62A-4C4D-8FF1-3F245ED6B8E7Q35047701-5979924A-5AE9-4B1D-8DCC-9FE14B91F57AQ35759193-FDDDC364-2A98-4C05-8B60-611AF2865100Q35819373-8857F4B2-D357-49E8-B6EC-61BC8770AF9AQ35841352-E8F9046C-02A4-4B8E-8305-3D6B8AEA2D84Q35841382-F1896835-EA27-48E4-816A-94C71B6C84D8Q37052630-70A45960-73FC-4E78-A7D0-039F73782BA7Q38043507-50769710-96B4-4170-A990-B1001CAF9936Q38044974-BD6F3452-4301-4AE8-97E7-EA56F8611AC3Q38442560-173E4566-6D83-4834-8BB8-BEF10F91FCD2Q40856064-0505B175-CE47-4B83-8947-254706B5255CQ41019245-48586E5D-E69C-427E-8BB0-3A62B3E927A9Q44905183-EEC8291F-BA06-4938-AD28-FBDE4D19C283Q45171050-1CC064ED-1785-4E83-B1BC-303296D7E472Q46542215-AE7A7810-AFEF-4BB6-AF5D-DAF9F815A635Q54568641-6B467C7A-B217-45E9-9067-2DAEB46C4EB0
P2860
Early clinical experience with a novel rapamycin derivative.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Early clinical experience with a novel rapamycin derivative.
@ast
Early clinical experience with a novel rapamycin derivative.
@en
Early clinical experience with a novel rapamycin derivative.
@nl
type
label
Early clinical experience with a novel rapamycin derivative.
@ast
Early clinical experience with a novel rapamycin derivative.
@en
Early clinical experience with a novel rapamycin derivative.
@nl
prefLabel
Early clinical experience with a novel rapamycin derivative.
@ast
Early clinical experience with a novel rapamycin derivative.
@en
Early clinical experience with a novel rapamycin derivative.
@nl
P1476
Early clinical experience with a novel rapamycin derivative.
@en
P2093
Björn Nashan
P356
10.1097/00007691-200202000-00010
P577
2002-02-01T00:00:00Z